Sujet(s)
Protéine cationique de l'éosinophile , Éosinophilie , Humains , Protéine cationique de l'éosinophile/sang , Éosinophilie/induit chimiquement , Éosinophilie/diagnostic , Exanthème/induit chimiquement , Exanthème/diagnostic , Syndrome d'hypersensibilité médicamenteuse/diagnostic , Syndrome d'hypersensibilité médicamenteuse/étiologie , Syndrome d'hypersensibilité médicamenteuse/immunologie , Syndrome d'hypersensibilité médicamenteuse/sang , Femelle , Mâle , Adulte d'âge moyen , AdulteRÉSUMÉ
Imatinib-induced skin rash poses a significant challenge for patients with gastrointestinal stromal tumor, often resulting in treatment interruption or discontinuation and subsequent treatment failure. However, the underlying mechanism of imatinib-induced skin rashes in gastrointestinal stromal tumor patients remains unclear. A total of 51 patients (27 with rash and 24 without rash) were enrolled in our study. Blood samples were collected concomitantly with the onset of clinical manifestations of rashes, and simultaneously collecting clinical relevant information. The imatinib concentration and untargeted metabolomics were performed by ultra-high-performance liquid chromatography-tandem mass spectrometry. There were no significant differences in age, gender, imatinib concentration and white blood cells count between the rash group and the control group. However, the rash group exhibited a higher eosinophil count (P<0.05) and lower lymphocyte count (P<0.05) compared to the control group. Untargeted metabolomics analysis found that 105 metabolites were significantly differentially abundant. The univariate analysis highlighted erucamide, linoleoylcarnitine, and valine betaine as potential predictive markers (AUC≥0.80). Further enriched pathway analysis revealed primary metabolic pathways, including sphingolipid signaling pathway, sphingolipid metabolism, cysteine and methionine metabolism, biosynthesis of unsaturated fatty acids, arginine and proline metabolism, and biosynthesis of amino acids. These findings suggest that the selected differential metabolites could serve as a foundation for the prediction and management of imatinib-induced skin rash in gastrointestinal stromal tumor patients.
Sujet(s)
Antinéoplasiques , Exanthème , Tumeurs gastro-intestinales , Tumeurs stromales gastro-intestinales , Mésilate d'imatinib , Métabolomique , Humains , Tumeurs stromales gastro-intestinales/traitement médicamenteux , Mésilate d'imatinib/effets indésirables , Mésilate d'imatinib/usage thérapeutique , Femelle , Mâle , Adulte d'âge moyen , Antinéoplasiques/effets indésirables , Antinéoplasiques/usage thérapeutique , Exanthème/induit chimiquement , Tumeurs gastro-intestinales/traitement médicamenteux , Sujet âgé , AdulteSujet(s)
Anticorps monoclonaux humanisés , Tumeurs cutanées , Humains , Anticorps monoclonaux humanisés/effets indésirables , Anticorps monoclonaux humanisés/usage thérapeutique , Mâle , Femelle , Sujet âgé , Tumeurs cutanées/traitement médicamenteux , Tumeurs cutanées/anatomopathologie , Adulte d'âge moyen , Exanthème/induit chimiquement , Exanthème/anatomopathologie , Toxidermies/étiologie , Toxidermies/diagnostic , Toxidermies/anatomopathologie , Syndrome de Sézary/traitement médicamenteux , Mycosis fongoïde/traitement médicamenteux , Mycosis fongoïde/anatomopathologieRÉSUMÉ
BACKGROUND: Rash is one of common adverse drug reaction and which have been reported in typical and atypical antipsychotics. Reports of lurasidone induced skin reactions are sparse. In this study, we report a case of rash caused by lurasidone. CASE PRESENTATION: A 63-year-old man with bipolar disorder (BD) who is treated by lurasidone. However, the patient presents a rash all over after lurasidone dose increasing from 40 mg/day to 60 mg/day. With the diagnosis of drug induced rash, lurasidone was discontinued, and the rash complete disappears within 2 weeks. In addition, all case reports about antipsychotics associated rash were reviewed by searching English and Chinese database including Pubmed, Embase, Cochrane Library, CNKI and Wanfang database. A total of 139 articles contained 172 patients were included in our study. The literature review and our case suggest that the cutaneous adverse events caused by antipsychotic drugs should not be ignored, particularly for the patient who was first use or at dose increasing of antipsychotic. CONCLUSIONS: In conclusion, we report a case of lurasidone related rash and review rash caused by antipsychotics. Psychiatrists should be alert to the possibility of the rash caused by antipsychotics, especially the patient was first use of antipsychotics or the antipsychotic dose was increasing.
Sujet(s)
Neuroleptiques , Trouble bipolaire , Exanthème , Chlorhydrate de lurasidone , Humains , Chlorhydrate de lurasidone/effets indésirables , Chlorhydrate de lurasidone/usage thérapeutique , Mâle , Trouble bipolaire/traitement médicamenteux , Neuroleptiques/effets indésirables , Neuroleptiques/usage thérapeutique , Adulte d'âge moyen , Exanthème/induit chimiquement , Peuples d'Asie de l'EstRÉSUMÉ
This column is the second of a 3-part series describing cases where general medical knowledge, including psychiatric and clinical pharmacology, were instrumental in determining dereliction and direct cause in a malpractice suit. This case summarizes how lamotrigine can cause dangerous consequences if its pharmacology is not properly understood. The case also illustrates how the 4 Ds of a forensic malpractice suit were met in this case. First, there was duty on the part of the prescriber which, if followed, would have prevented or minimized the damages experienced by the patient. Dereliction in the performance of a patient-physician treatment contract was a direct cause of the development of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in this patient. An immune-mediated reaction to lamotrigine or one of its metabolites has been extensively reported in the literature, with the risk of this reaction increasing at higher doses and with more rapid titration, fulfilling the elements of direct cause. Dereliction implies a deviation from the standard of care. On the basis of the clinical information from the package insert, more likely than not a deviation from the standard of care occurred in this case when lamotrigine was titrated faster than recommended by the package insert.
Sujet(s)
Lamotrigine , Syndrome de Stevens-Johnson , Humains , Lamotrigine/effets indésirables , Lamotrigine/pharmacologie , Syndrome de Stevens-Johnson/étiologie , Triazines/effets indésirables , Adulte , Femelle , Faute professionnelle , Mâle , Anticonvulsivants/effets indésirables , Anticonvulsivants/pharmacologie , Exanthème/induit chimiquementSujet(s)
Anticorps monoclonaux humanisés , Toxidermies , Psoriasis , Humains , Anticorps monoclonaux humanisés/effets indésirables , Toxidermies/étiologie , Toxidermies/anatomopathologie , Psoriasis/traitement médicamenteux , Psoriasis/induit chimiquement , Psoriasis/anatomopathologie , Antinéoplasiques immunologiques/effets indésirables , Exanthème/induit chimiquement , Exanthème/anatomopathologie , Mâle , Femelle , Sujet âgéRÉSUMÉ
Rash is one of the commonly observed adverse events with brentuximab vedotin (BV), a CD30-targeted antibody-drug conjugate used to treat cutaneous T-cell lymphoma (CTCL). However, clinical and histopathologic characterization of BV-associated rash (BVAR) is limited. Distinguishing BVAR from a patient's underlying CTCL can be challenging and can lead to treatment interruptions or even premature drug discontinuation. We performed a thorough clinical and histopathologic retrospective characterization of BVAR from a single institution. Utilizing polymerase chain reaction (PCR) and T-cell receptor high-throughput sequencing (TCR-HTS), we were able to isolate skin biopsy specimens from rash clinically suggestive of BVAR that also lacked a dominant TCR clone. A retrospective evaluation was performed of 26 biopsy specimens from 14 patients. Clinical features of BVAR included predominantly morbilliform or maculopapular morphology, delayed onset, and the trend toward moderate to severe classification, often requiring oral steroids. Most histopathologic specimens (25/26) showed spongiotic dermatitis as the primary reaction pattern. Many cases showed subtle findings to support a background interface or lichenoid eruption. Langerhans cell microabscesses were seen in one-fourth of specimens, and eosinophils were present in over one-half of the specimens. There were focal features mimicking CTCL, but these were not prominent. In 17 specimens with immunohistochemistry, the CD4:CD8 ratio in intraepidermal lymphocytes was relatively normal (1-6:1) in 65% (11/17) and 1:1 in 35% (6/17), demonstrating a trend toward increased CD8-positive cells compared with baseline CTCL. We have identified features that can help distinguish BVAR from a patient's CTCL, which can, in turn, help guide appropriate clinical management.
Sujet(s)
Brentuximab védotine , Toxidermies , Exanthème , Lymphome T cutané , Humains , Brentuximab védotine/effets indésirables , Femelle , Mâle , Adulte d'âge moyen , Études rétrospectives , Toxidermies/anatomopathologie , Toxidermies/étiologie , Toxidermies/diagnostic , Sujet âgé , Exanthème/induit chimiquement , Exanthème/anatomopathologie , Adulte , Lymphome T cutané/anatomopathologie , Lymphome T cutané/traitement médicamenteux , Immunoconjugués/effets indésirables , Tumeurs cutanées/anatomopathologie , Tumeurs cutanées/traitement médicamenteux , Antinéoplasiques immunologiques/effets indésirables , Biopsie , Séquençage nucléotidique à haut débit , Sujet âgé de 80 ans ou plus , Peau/anatomopathologie , Peau/effets des médicaments et des substances chimiques , Peau/immunologie , Diagnostic différentielRÉSUMÉ
Epidermal growth factor receptor inhibitors (EGFRis) are used to treat many cancers, but their use is complicated by the development of a skin rash that may be severe, limiting their use and adversely affecting patient quality of life. Most studies of EGFRi-induced rash have focused on the fully developed stage of this skin disorder, and early pathological changes remain unclear. We analyzed high-throughput transcriptome sequencing of skin samples from rats exposed to the EGFRi afatinib and identified that keratinocyte activation is an early pathological alteration in EGFRi-induced rash. Mechanistically, the induction of S100 calcium-binding protein A9 (S100A9) occurred before skin barrier disruption and led to keratinocyte activation, resulting in expression of specific cytokines, chemokines, and surface molecules such as interleukin 6 (Il6) and C-C motif chemokine ligand 2 (CCL2) to recruit and activate monocytes through activation of the Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway, further recruiting more immune cells. Topical JAK inhibition suppressed the recruitment of immune cells and ameliorated the severity of skin rash in afatinib-treated rats and mice with epidermal deletion of EGFR, while having no effect on EGFRi efficacy in tumor-bearing mice. In a pilot clinical trial (NCT05120362), 11 patients with EGFRi-induced rash were treated with delgocitinib ointment, resulting in improvement in rash severity by at least one grade in 10 of them according to the MASCC EGFR inhibitor skin toxicity tool (MESTT) criteria. These findings provide a better understanding of the early pathophysiology of EGFRi-induced rash and suggest a strategy to manage this condition.
Sujet(s)
Récepteurs ErbB , Exanthème , Inhibiteurs des Janus kinases , Animaux , Femelle , Humains , Mâle , Souris , Adulte d'âge moyen , Rats , Administration par voie topique , Afatinib/pharmacologie , Afatinib/usage thérapeutique , Récepteurs ErbB/antagonistes et inhibiteurs , Récepteurs ErbB/métabolisme , Exanthème/induit chimiquement , Exanthème/anatomopathologie , Inhibiteurs des Janus kinases/pharmacologie , Inhibiteurs des Janus kinases/usage thérapeutique , Janus kinases/métabolisme , Janus kinases/antagonistes et inhibiteurs , Kératinocytes/effets des médicaments et des substances chimiques , Kératinocytes/métabolisme , Kératinocytes/anatomopathologie , Inhibiteurs de protéines kinases/pharmacologie , Inhibiteurs de protéines kinases/usage thérapeutique , Études prospectivesSujet(s)
Syndrome d'hypersensibilité médicamenteuse , Exanthème , Humains , Syndrome d'hypersensibilité médicamenteuse/étiologie , Syndrome d'hypersensibilité médicamenteuse/diagnostic , Mâle , Exanthème/induit chimiquement , Sujet âgé , Tumeurs de la prostate/traitement médicamenteux , Adulte d'âge moyen , Toxidermies/étiologieRÉSUMÉ
Mogamulizumab, a monoclonal antibody directed against CC chemokine receptor 4, is approved as a second-line treatment of mycosis fungoides and Sézary syndrome. One of the most common side effects is mogamulizumab-associated rash (MAR), which can present in a variety of clinical and histological types. Clinically, it can be difficult to differentiate between MAR and progression of the underlying disease, so histological examination is crucial for clinicopathological correlation. Current data analyses suggest that MAR is more common in patients with Sézary syndrome and is associated with a significantly better response to treatment, making the distinction from disease progression particularly important. The management of MAR depends on its severity, and therapy may need to be paused. This article presents three cases from our clinic and reviews the current literature on MAR. It emphasizes the importance of understanding MAR in the management of patients with cutaneous lymphomas.
Sujet(s)
Anticorps monoclonaux humanisés , Exanthème , Tumeurs cutanées , Humains , Anticorps monoclonaux humanisés/effets indésirables , Anticorps monoclonaux humanisés/usage thérapeutique , Mâle , Femelle , Sujet âgé , Tumeurs cutanées/traitement médicamenteux , Tumeurs cutanées/anatomopathologie , Adulte d'âge moyen , Exanthème/induit chimiquement , Exanthème/anatomopathologie , Toxidermies/étiologie , Toxidermies/diagnostic , Toxidermies/anatomopathologie , Syndrome de Sézary/traitement médicamenteux , Syndrome de Sézary/anatomopathologieSujet(s)
Antifongiques , Toxidermies , Itraconazole , Humains , Itraconazole/effets indésirables , Itraconazole/usage thérapeutique , Antifongiques/effets indésirables , Toxidermies/étiologie , Toxidermies/anatomopathologie , Toxidermies/diagnostic , Mâle , Femelle , Adulte d'âge moyen , Exanthème/induit chimiquementSujet(s)
Toxidermies , Inhibiteurs de points de contrôle immunitaires , Association triméthoprime-sulfaméthoxazole , Humains , Inhibiteurs de points de contrôle immunitaires/effets indésirables , Mâle , Femelle , Toxidermies/étiologie , Toxidermies/épidémiologie , Association triméthoprime-sulfaméthoxazole/effets indésirables , Adulte d'âge moyen , Sujet âgé , Incidence , Exanthème/induit chimiquement , Études rétrospectives , Hormones corticosurrénaliennes/usage thérapeutique , Hormones corticosurrénaliennes/administration et posologie , Glucocorticoïdes/effets indésirables , Glucocorticoïdes/administration et posologie , Glucocorticoïdes/usage thérapeutiqueRÉSUMÉ
BACKGROUND: Oncological therapies can cause a variety of mucocutaneous adverse events. Exanthematous adverse events can be challenging in the context of the urgent need for cancer treatment due to their spread, sometimes rapid progression, and mucous membrane or organ involvement. MATERIALS AND METHODS: This article provides an overview of the most important exanthematic dermatoses as side effects of modern drug-based tumor therapies with diagnostic and therapeutic information for clinicians, taking into account the current literature and guidelines. RESULTS: Exanthematous adverse events of immune checkpoint inhibitors, EGFR antagonists, kinase inhibitors, bispecific Tcell engagers, and the CCR4 inhibitor mogamulizumab are reviewed in detail. CONCLUSIONS: Cutaneous side effects are common across all drug classes and cover a broad spectrum. While some adverse events are specific to one drug class, many exanthemas can occur with both oncological immunotherapies and various targeted therapies. A reliable diagnosis, dose adjustment or discontinuation of the offending agent in consultation with the treating oncologists and appropriate symptomatic therapy are important for correct management. In the case of severe, life-threatening drug reactions, however, permanent discontinuation of the drug is essential.
Sujet(s)
Toxidermies , Exanthème , Inhibiteurs de points de contrôle immunitaires , Immunothérapie , Humains , Exanthème/induit chimiquement , Exanthème/thérapie , Toxidermies/thérapie , Toxidermies/diagnostic , Toxidermies/étiologie , Toxidermies/immunologie , Immunothérapie/effets indésirables , Immunothérapie/méthodes , Inhibiteurs de points de contrôle immunitaires/effets indésirables , Anticorps monoclonaux humanisés/effets indésirables , Anticorps monoclonaux humanisés/usage thérapeutique , Tumeurs/traitement médicamenteux , Tumeurs/immunologie , Thérapie moléculaire ciblée/effets indésirables , Antinéoplasiques/effets indésirables , Antinéoplasiques/usage thérapeutique , Inhibiteurs de protéines kinases/effets indésirables , Inhibiteurs de protéines kinases/usage thérapeutiqueRÉSUMÉ
Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is classically considered a low-risk, self-limiting eruption lacking systemic manifestations and sparing facial and mucosal areas. We present 7 inpatients meeting diagnostic criteria for SDRIFE with concomitant systemic manifestations ± high-risk facial involvement acutely after antibiotic exposure (mean latency 6.71 days). These cases deviate from classic, self-limited SDRIFE and represent a unique phenotype of SDRIFE, characterized by coexisting extracutaneous manifestations. Onset of systemic stigmata coincided with or preceded cutaneous involvement in 4 and 3 patients, respectively. All patients developed peripheral eosinophilia and 6 patients had ≥ 2 extracutaneous systems involved. Facial involvement, a high-risk feature associated with severe cutaneous adverse reactions but atypical in classic SDRIFE, occurred in 4 cases. Patients had favorable clinical outcomes following drug cessation and treatment with 4-6 week corticosteroid tapers. We suggest that baseline labs be considered in hospitalized patients with antibiotic-induced SDRIFE. These patients may also necessitate systemic therapy given extracutaneous involvement, deviating from standard SDRIFE treatment with drug cessation alone.
Sujet(s)
Antibactériens , Toxidermies , Exanthème , Phénotype , Humains , Mâle , Femelle , Adulte d'âge moyen , Exanthème/induit chimiquement , Exanthème/diagnostic , Antibactériens/effets indésirables , Toxidermies/étiologie , Toxidermies/diagnostic , Toxidermies/anatomopathologie , Sujet âgé , Adulte , Hospitalisation/statistiques et données numériques , Éosinophilie/diagnostic , Éosinophilie/induit chimiquementRÉSUMÉ
BACKGROUND: Cutaneous manifestations of drug-induced type IV reactions vary widely, with symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) being a less common presentation. Corticosteroids (CS), primarily known for their anti-inflammatory effects, rarely induce hypersensitivity reactions. OBJECTIVE: The aim of this case series is to report four cases of SDRIFE following systemic prednisolone therapy and to review existing CS classification proposals to better understand cross-reactivity of CS. PATIENTS/METHODS: Patients recruited at a German dermatology centre underwent allergologic evaluation including prick and patch testing with various CS. Positive cases underwent oral challenge testing with alternative agents. The classification systems of Coopman et al. and Baeck et al. were taken into account. DISCUSSION: Despite a paucity of literature, CS-induced type IV reactions do occur, including SDRIFE. Classification systems based on chemical structure provide insight into cross-reactivity patterns. Provocation tests with alternative CS highlight the complexity of managing CS hypersensitivity. CONCLUSION: SDRIFE may develop following systemic prednisolone therapy. Classification systems are helpful in understanding cross-reactivity and help in the selection of alternative preparations but are not always reliable. Individualised assessment is crucial for managing CS hypersensitivity, with consideration of alternative agents and emergency use of CS when necessary.
Sujet(s)
Toxidermies , Exanthème , Prednisolone , Humains , Femelle , Toxidermies/étiologie , Toxidermies/diagnostic , Exanthème/induit chimiquement , Adulte d'âge moyen , Prednisolone/usage thérapeutique , Prednisolone/administration et posologie , Mâle , Adulte , Réactions croisées , Sujet âgé , Tests épicutanés , Glucocorticoïdes/usage thérapeutique , Glucocorticoïdes/administration et posologieSujet(s)
Amikacine , Réactions croisées , Désensibilisation immunologique , Néomycine , Humains , Désensibilisation immunologique/méthodes , Amikacine/effets indésirables , Amikacine/usage thérapeutique , Néomycine/effets indésirables , Antibactériens/effets indésirables , Exanthème/induit chimiquement , Hypersensibilité médicamenteuse/thérapie , Hypersensibilité médicamenteuse/immunologie , Hypersensibilité médicamenteuse/diagnostic , Femelle , Mâle , Adulte d'âge moyenRÉSUMÉ
PURPOSE: Immune-related cutaneous adverse events (ircAE) occur in ≥50% of patients treated with checkpoint inhibitors, but the underlying mechanisms for ircAEs are poorly understood. EXPERIMENTAL DESIGN: Phenotyping/biomarker analyses were conducted in 200 patients on checkpoint inhibitors [139 with ircAEs and 61 without (control group)] to characterize their clinical presentation and immunologic endotypes. Cytokines were evaluated in skin biopsies, skin tape strip extracts, and plasma using real-time PCR and Meso Scale Discovery multiplex cytokine assays. RESULTS: Eight ircAE phenotypes were identified: pruritus (26%), maculopapular rash (MPR; 21%), eczema (19%), lichenoid (11%), urticaria (8%), psoriasiform (6%), vitiligo (5%), and bullous dermatitis (4%). All phenotypes showed skin lymphocyte and eosinophil infiltrates. Skin biopsy PCR revealed the highest increase in IFNγ mRNA in patients with lichenoid (P < 0.0001) and psoriasiform dermatitis (P < 0.01) as compared with patients without ircAEs, whereas the highest IL13 mRNA levels were detected in patients with eczema (P < 0.0001, compared with control). IL17A mRNA was selectively increased in psoriasiform (P < 0.001), lichenoid (P < 0.0001), bullous dermatitis (P < 0.05), and MPR (P < 0.001) compared with control. Distinct cytokine profiles were confirmed in skin tape strip and plasma. Analysis determined increased skin/plasma IL4 cytokine in pruritus, skin IL13 in eczema, plasma IL5 and IL31 in eczema and urticaria, and mixed-cytokine pathways in MPR. Broad inhibition via corticosteroids or type 2 cytokine-targeted inhibition resulted in clinical benefit in these ircAEs. In contrast, significant skin upregulation of type 1/type 17 pathways was found in psoriasiform, lichenoid, bullous dermatitis, and type 1 activation in vitiligo. CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.
Sujet(s)
Cytokines , Inhibiteurs de points de contrôle immunitaires , Humains , Mâle , Femelle , Inhibiteurs de points de contrôle immunitaires/effets indésirables , Adulte d'âge moyen , Sujet âgé , Cytokines/métabolisme , Peau/anatomopathologie , Peau/immunologie , Peau/métabolisme , Peau/effets des médicaments et des substances chimiques , Adulte , Toxidermies/étiologie , Toxidermies/anatomopathologie , Toxidermies/immunologie , Prurit/immunologie , Prurit/induit chimiquement , Prurit/anatomopathologie , Prurit/étiologie , Prurit/génétique , Tumeurs/traitement médicamenteux , Tumeurs/immunologie , Tumeurs/anatomopathologie , Maladies de la peau/induit chimiquement , Maladies de la peau/immunologie , Maladies de la peau/anatomopathologie , Maladies de la peau/étiologie , Exanthème/induit chimiquement , Exanthème/anatomopathologie , Sujet âgé de 80 ans ou plus , Psoriasis/traitement médicamenteux , Psoriasis/immunologie , Psoriasis/anatomopathologie , Psoriasis/génétique , Eczéma/anatomopathologie , Eczéma/traitement médicamenteuxSujet(s)
Antifongiques , Toxidermies , Itraconazole , Humains , Itraconazole/effets indésirables , Itraconazole/usage thérapeutique , Antifongiques/effets indésirables , Toxidermies/étiologie , Toxidermies/anatomopathologie , Toxidermies/diagnostic , Exanthème/induit chimiquement , Exanthème/anatomopathologie , Mâle , Femelle , Adulte d'âge moyenRÉSUMÉ
OBJECTIVE: This analysis of the first-line cohort of LASER201 study evaluated the efficacy and safety of lazertinib 240 mg as a frontline therapy for epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). METHODS: A total of 43 patients, with EGFR mutation-positive (Exon19Del, n = 24; L858R, n = 18; G719X, n = 1) locally advanced or metastatic NSCLC who had not previously received EGFR tyrosine kinase inhibitor (EGFR TKI) therapy, received once-daily lazertinib 240 mg. EGFR mutation status was confirmed by local or central testing. The primary endpoint was objective response rate (ORR) assessed by blinded independent central review. Secondary efficacy endpoints included duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), tumor shrinkage, and overall survival (OS). RESULTS: At the primary data cut-off (DCO; January 8, 2021), the ORR was 70 % (95 % confidence interval [CI]: 56.0-83.5), DCR was 86 % (95 % CI: 75.7-96.4) and the median DoR was 23.5 (95 % CI: 12.5-not reached) months. The median PFS was 24.6 (95 % CI: 12.2-30.2) months. At the final DCO (March 30, 2023), the median OS was not estimable and the median follow-up duration for OS was 55.2 [95 % CI: 22.8-55.7] months. OS rates at 36 months and 54 months were 66 % (95 % CI: 47.5-79.3 %) and 55 % (95 % CI: 36.6-70.7 %), respectively. The most commonly reported TEAEs were rash (54 %), diarrhea (47 %), pruritus (35 %), and paresthesia (35 %). No drug-related rash or pruritus TEAEs of grade 3 or higher were reported. Diarrhea and paresthesia of grade 3 or higher were reported in 3 (7 %) and 1 (2 %) patients, respectively. CONCLUSION: This analysis demonstrated long-term clinical benefit with lazertinib 240 mg in patients with EGFR-mutated NSCLC who had not previously received EGFR TKIs. The safety profile for lazertinib was tolerable and consistent with that previously reported.